IL33 and neoplasm: An IL-33 blockade restricts NSCLC outgrowth, abrogates polarization of M2 tumor-associated macrophages (TAMs), and reduces accumulations of Treg cells in tumor tissues, thus representing an effective and promising strategy for NSCLC treatment [2].